Clinical Trial Update: SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 safety study SG301 in relapsed or refractory multiple myeloma and other hematologic malignancies is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancy
• Or Refractory Multiple Myeloma

Drugs mentioned

• SG301

Snippet

Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Conditions: Relapsed or Refractory Multiple Myeloma, Hematological Malignancy | Phase 1 | Status: ACTIVE_NOT_RECRUITING